AACP
CYTK icon

Advantage Alpha Capital Partners’s Cytokinetics CYTK Stock Holding History

Advantage Alpha Capital Partners’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-8,292
Closed -$438K – 161
2024
Q3 		$438K Buy
+8,292
New +$462K 0.1% 146

Other funds holding CYTK

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Advantage Alpha Capital Partners's CYTK Position: Q4 2024 in Review

Advantage Alpha Capital Partners sold out of Cytokinetics (CYTK) in Q4 2024, closing a stake of 8,292 shares — an estimated $438K sold.

Advantage Alpha Capital Partners first reported a position in CYTK in Q3 2024 and held it in 1 quarter. The position peaked at $438K in Q3 2024. 346 funds tracked by Wall St. Rank hold CYTK as of Q4 2024.

  • Advantage Alpha Capital Partners reported no remaining Cytokinetics position as of Q4 2024 after selling out during the quarter.
  • Advantage Alpha Capital Partners sold 8,292 Cytokinetics shares in Q4 2024, an estimated $438K.
  • Advantage Alpha Capital Partners first reported a position in Cytokinetics in Q3 2024 and held it in 1 quarter.
  • Advantage Alpha Capital Partners's Cytokinetics position peaked at $438K in Q3 2024.
  • 346 funds tracked by Wall St. Rank held Cytokinetics as of Q4 2024.

Based on Advantage Alpha Capital Partners's 13F filing for Q4 2024, filed 11 Feb 2025.